



**Office of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**May 13, 2008 6:30 – 9:00 p.m.**

- 1. Executive Session** **6:30 - 7:00**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**

(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
  - Annual completion of Disclosure Forms
  - Department of Mental Health review of mental health classes/criteria
- 4. Medical Director Update** **7:15 - 7:20**
  - Clinical Programs Update
  - Prescriber Comments
- 5. Follow-up Items from Previous Meeting** **7:20 - 7:20**
  - None
- 6. Clinical Update: Drug Reviews** **7:20 – 8:10**

(Public comment prior to Board action)

  - Flector<sup>®</sup> (diclofenac epolamine 1.3 %) Transdermal Patch
  - Iquix<sup>®</sup> (levofloxacin 1.5 %) Ophthalmic Solution
  - Lidoderm<sup>®</sup> (lidocaine 5 %) Transdermal Patch
  - Somatuline<sup>®</sup> (lanreotide) Depot Injection
  - Tysabri<sup>®</sup> (natalizumab) Intravenous Injection (in Crohn's & MS & FDA warning)
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **8:10 – 8:25**

(Public comment prior to Board action)

  - Miscellaneous: Soliris<sup>®</sup> (Paroxysmal Nocturnal Hemoglobinuria Injectable) – further definition of criteria
  - Pulmonary: Antihistamines: 2<sup>nd</sup> Generation (Allegra<sup>®</sup> (fexofenadine) ODT (orally disintegrating tablet))
  - Humira<sup>®</sup> (new indications)
  - Remicade<sup>®</sup> (for indications other than Crohn's)
- 8. Drug Classes – New** **8:25 – 8:30**
  - Analgesics: Local Anesthetics: Transdermal

- 9. RetroDUR** **8:30 - 8:45**
- Acetaminophen > 4 grams/day
  - Advair®
  - Cost Savings/Clinical Analysis of Prior Initiatives
    - Angiotensin Receptor Blocker Step Therapy Cost Savings
- 10. New Drug Product Plan Exclusions (Consent Agenda Topic)** **8:45 - 8:50**
- 11. Updated New-to-Market Drug Monitoring Log** **8:50 - 8:55**
- 12. General Announcements** **8:55 - 9:00**
- FDA Safety Alerts**
- Singulair® (montelukast) – behavior/mood changes
  - Neupro® (rotigotine transdermal system) – crystals in patch
  - Cellcept® (mycophenolate mofetil)/Myfortic® (mycophenolate acid) – association with PML
  - Digitek® (digoxin tablets) – Class I recalls – fax blast to pharmacies
- 13. Adjourn** **9:00**